Analyst Price Target is $13.50
▲ +844.06% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Immuneering in the last 3 months. The average price target is $13.50, with a high forecast of $25.00 and a low forecast of $3.00. The average price target represents a 844.06% upside from the last price of $1.43.
Current Consensus is
Moderate Buy
The current consensus among 8 contributing investment analysts is to moderate buy stock in Immuneering. This Moderate Buy consensus rating has held steady for over two years.
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More